KalVista Pharmaceuticals (KALV) Research & Development (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Research & Development of $15.2 million in Q3 2025, down 4.59% quarter-over-quarter from $15.9 million in Q2 2025, and down 43.03% year-over-year from $26.6 million in Q3 2024.
KalVista Pharmaceuticals' Research & Development history runs 12 years deep, the most recent figure standing at $15.2 million for Q3 2025.
- In Q3 2025, Research & Development fell 43.03% year-over-year to $15.2 million; the TTM figure through Jul 2025 stood at $74.3 million (down 20.54% YoY), while the FY2025 annual figure was $71.7 million, down 16.78% from the prior year.
- Research & Development came in at $15.2 million for Q3 2025 at KalVista Pharmaceuticals, down from $15.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $26.6 million in Q3 2024 to a low of $9.1 million in Q1 2021.
- A 5-year average of $18.4 million and a median of $18.6 million in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 116.97% in 2022 and sank 43.03% in 2025, its largest moves.
- KalVista Pharmaceuticals' Research & Development stood at $17.5 million in 2021, then increased by 3.03% to $18.1 million in 2022, then grew by 5.6% to $19.1 million in 2023, then slipped by 12.99% to $16.6 million in 2024, then dropped by 8.72% to $15.2 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $15.2 million, $15.9 million, and $16.6 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 15.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 15.16 Mn |
| Apr 30, 2025 | 15.89 Mn |
| Oct 31, 2024 | 16.61 Mn |
| Jul 31, 2024 | 26.61 Mn |
| Apr 30, 2024 | 25.25 Mn |
| Jan 31, 2024 | 22.52 Mn |
| Oct 31, 2023 | 19.09 Mn |
| Jul 31, 2023 | 19.31 Mn |
| Apr 30, 2023 | 23.95 Mn |
| Jan 31, 2023 | 20.06 Mn |
| Oct 31, 2022 | 18.08 Mn |
| Jul 31, 2022 | 18.19 Mn |
| Apr 30, 2022 | 19.21 Mn |
| Jan 31, 2022 | 19.74 Mn |
| Oct 31, 2021 | 17.55 Mn |
| Jul 31, 2021 | 13.67 Mn |
| Apr 30, 2021 | 11.88 Mn |
| Jan 31, 2021 | 9.10 Mn |
| Oct 31, 2020 | 9.15 Mn |
| Jul 31, 2020 | 11.17 Mn |
| Apr 30, 2020 | 9.49 Mn |
| Jan 31, 2020 | 11.23 Mn |
| Oct 31, 2019 | 9.79 Mn |
| Jul 31, 2019 | 9.69 Mn |
| Apr 30, 2019 | 11.14 Mn |
| Jan 31, 2019 | 7.65 Mn |
| Oct 31, 2018 | 7.88 Mn |
| Jul 31, 2018 | 8.36 Mn |
| Apr 30, 2018 | 5.85 Mn |
| Jan 31, 2018 | 4.55 Mn |
| Oct 31, 2017 | 4.36 Mn |
| Jul 31, 2017 | 3.48 Mn |
| Apr 30, 2017 | 3.00 Mn |
| Jan 31, 2017 | 3.34 Mn |
| Oct 31, 2016 | 2.93 Mn |
| Jul 31, 2016 | 3.40 Mn |
| Mar 31, 2016 | 3.53 Mn |
| Dec 31, 2015 | 4.26 Mn |
| Sep 30, 2015 | 3.53 Mn |
| Jun 30, 2015 | 4.50 Mn |
| Mar 31, 2015 | 3.90 Mn |
| Sep 30, 2014 | 2.09 Mn |
| Jun 30, 2014 | 1.75 Mn |
| Mar 31, 2014 | 1.43 Mn |